[Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].
BACKGROUND
Vitamin K epoxide reductase complex subunit I (VKORC1) is a key enzyme in the vitamin K cycle, cofactor required for the activation of vitamin K-dependent clotting factors.


METHODS
VKORC1 recycles vitamin K 2,3 epoxide back to active vitamin K hydroquinone, an important factor for the carboxylation step of clotting factors. VKORC1 is the target enzyme of inhibition by oral anticoagulants or anti-vitamin K (warfarin, acenocoumarol).


CONCLUSIONS
We show here the clinical consequences of genetic variations of VKORC1 during VKA therapy.
Loriot
M-A
MA
Inserm UMR-S775, service de toxicologie moléculaire, université René-Descartes, centre universitaire des Saints-Pères, 45, rue des Saints-Pères, 75006 Paris, France. marie-anne.loriot@univ-paris5.fr
Beaune
P
P
D000284:Administration, Oral; D000465:Algorithms; D000925:Anticoagulants / Q000494:pharmacology*; D004351:Drug Resistance / Q000235:genetics; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics* / Q000378:metabolism; D009154:Mutation; D011110:Polymorphism, Genetic; D014812:Vitamin K / Q000235:genetics / Q000378:metabolism*; D064417:Vitamin K Epoxide Reductases
D000925:Anticoagulants; D014812:Vitamin K; D006899:Mixed Function Oxygenases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases